215 related articles for article (PubMed ID: 34136421)
41. Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation.
Behm B; Di Fazio P; Michl P; Neureiter D; Kemmerling R; Hahn EG; Strobel D; Gress T; Schuppan D; Wissniowski TT
Gut; 2016 Jan; 65(1):134-43. PubMed ID: 25524262
[TBL] [Abstract][Full Text] [Related]
42. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.
Hebb JPO; Mosley AR; Vences-Catalán F; Rajasekaran N; Rosén A; Ellmark P; Felsher DW
Cancer Immunol Immunother; 2018 Jan; 67(1):47-60. PubMed ID: 28905118
[TBL] [Abstract][Full Text] [Related]
43. Anti-OX40 Antibody Combined with HBc VLPs Delays Tumor Growth in a Mouse Colon Cancer Model.
Liu JJ; Su QD; Yi Y; Shen LP; Bi SL
Biomed Environ Sci; 2024 Feb; 37(2):187-195. PubMed ID: 38582981
[TBL] [Abstract][Full Text] [Related]
44. OX40 agonist combined with irreversible electroporation synergistically eradicates established tumors and drives systemic antitumor immune response in a syngeneic pancreatic cancer model.
Zhang QW; Guo XX; Zhou Y; Wang QB; Liu Q; Wu ZY; Ding XY
Am J Cancer Res; 2021; 11(6):2782-2801. PubMed ID: 34249428
[TBL] [Abstract][Full Text] [Related]
45. Neoantigen Immunotherapeutic-Gel Combined with TIM-3 Blockade Effectively Restrains Orthotopic Hepatocellular Carcinoma Progression.
Zhao Q; Wang Y; Zhao B; Chen H; Cai Z; Zheng Y; Zeng Y; Zhang D; Liu X
Nano Lett; 2022 Mar; 22(5):2048-2058. PubMed ID: 35133159
[TBL] [Abstract][Full Text] [Related]
46. Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccination.
Chu Y; Li R; Qian L; Liu F; Xu R; Meng F; Ke Y; Shao J; Yu L; Liu Q; Liu B
Cancer Sci; 2021 Nov; 112(11):4490-4500. PubMed ID: 34537997
[TBL] [Abstract][Full Text] [Related]
47. OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive Function.
Polesso F; Sarker M; Weinberg AD; Murray SE; Moran AE
J Immunol; 2019 Oct; 203(7):2011-2019. PubMed ID: 31434709
[TBL] [Abstract][Full Text] [Related]
48. Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment.
Bresson D; Fousteri G; Manenkova Y; Croft M; von Herrath M
J Autoimmun; 2011 Dec; 37(4):342-51. PubMed ID: 22063316
[TBL] [Abstract][Full Text] [Related]
49. Intratumoural GM-CSF microspheres and CTLA-4 blockade enhance the antitumour immunity induced by thermal ablation in a subcutaneous murine hepatoma model.
Chen Z; Shen S; Peng B; Tao J
Int J Hyperthermia; 2009 Aug; 25(5):374-82. PubMed ID: 19479598
[TBL] [Abstract][Full Text] [Related]
50. Challenges and opportunities in the development of combination immunotherapy with OX40 agonists.
Redmond WL
Expert Opin Biol Ther; 2023; 23(9):901-912. PubMed ID: 37587644
[TBL] [Abstract][Full Text] [Related]
51. Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve.
Fabian KP; Padget MR; Fujii R; Schlom J; Hodge JW
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33602696
[TBL] [Abstract][Full Text] [Related]
52. Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity.
Sturgill ER; Rolig AS; Linch SN; Mick C; Kasiewicz MJ; Sun Z; Traber PG; Shlevin H; Redmond WL
Oncoimmunology; 2021 Mar; 10(1):1892265. PubMed ID: 33717655
[TBL] [Abstract][Full Text] [Related]
53. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.
Shibahara I; Saito R; Zhang R; Chonan M; Shoji T; Kanamori M; Sonoda Y; Kumabe T; Kanehira M; Kikuchi T; So T; Watanabe T; Takahashi H; Iwabuchi E; Tanaka Y; Shibahara Y; Sasano H; Ishii N; Tominaga T
Mol Cancer; 2015 Feb; 14():41. PubMed ID: 25744203
[TBL] [Abstract][Full Text] [Related]
54. Targeting squalene epoxidase restores anti-PD-1 efficacy in metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinoma.
Wen J; Zhang X; Wong CC; Zhang Y; Pan Y; Zhou Y; Cheung AH; Liu Y; Ji F; Kang X; Liu D; Yu J
Gut; 2024 May; ():. PubMed ID: 38744443
[TBL] [Abstract][Full Text] [Related]
55. CD8
Xu C; Lu X; Liu W; Chen A; Meng G; Zhang H; Li B; Zhang Y; Wu J; Wei J
J Transl Med; 2018 May; 16(1):132. PubMed ID: 29784005
[TBL] [Abstract][Full Text] [Related]
56. Reprogramming macrophage by targeting VEGF and CD40 potentiates OX40 immunotherapy.
Liu Y; Ma Q; Yang K; Zhang D; Li F; Chen J; Zhou F; Wang H; Li N; Wang Y; Cao Y; Zhang C; Li X; Zhang H; Wang W; Li Y
Biochem Biophys Res Commun; 2024 Feb; 698():149546. PubMed ID: 38266314
[TBL] [Abstract][Full Text] [Related]
57. Targeting ALCAM in the cryo-treated tumour microenvironment successfully induces systemic anti-tumour immunity.
Kudo-Saito C; Fuwa T; Kawakami Y
Eur J Cancer; 2016 Jul; 62():54-61. PubMed ID: 27208904
[TBL] [Abstract][Full Text] [Related]
58. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575
[TBL] [Abstract][Full Text] [Related]
59. Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.
Li G; Liu D; Cooper TK; Kimchi ET; Qi X; Avella DM; Li N; Yang QX; Kester M; Rountree CB; Kaifi JT; Cole DJ; Rockey DC; Schell TD; Staveley-O'Carroll KF
J Hepatol; 2017 Jan; 66(1):75-85. PubMed ID: 27520877
[TBL] [Abstract][Full Text] [Related]
60. Combined OX40 Agonist and PD-1 Inhibitor Immunotherapy Improves the Efficacy of Vascular Targeted Photodynamic Therapy in a Urothelial Tumor Model.
Alvim RG; Georgala P; Nogueira L; Somma AJ; Nagar K; Thomas J; Alvim L; Riegel A; Hughes C; Chen J; Reis AB; Lebdai S; Scherz A; Zanganeh S; Gardner R; Kim K; Coleman JA
Molecules; 2021 Jun; 26(12):. PubMed ID: 34205347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
